ExCellThera was established through a partnership between the Institute for Research in Immunology and Cancer – Commercialization of Research (IRICoR) and the Centre for Commercialization of Regenerative Medicine (CCRM). ExCellThera is developing product and service solutions based on novel proprietary intellectual property developed at the University of Montreal’s (UdeM) Institute for Research in Immunology and Cancer (IRIC), and the University of Toronto’s Institute of Biomaterials and Biomedical Engineering (IBBME).
Institute for Research in Immunology and Cancer – Commercialization of Research
The Institute for Research in Immunology and Cancer – Commercialization of Research (IRICoR) is a not-for-profit drug discovery and commercialization centre based at the Institute for Research in Immunology and Cancer (IRIC) of the University of Montreal (UdeM). IRICoR’s main objective is to rapidly translate highly innovative scientific projects from IRIC, UdeM and various centres into high value novel therapies in oncology, immunology and related indications through strong partnerships with the private sector – thereby efficiently bridging the innovation translation gap between early stage academic research and industry. For more information: www.iricor.ca
Centre for Commercialization of Regenerative Medicine
CCRM, a Canadian not-for-profit organization funded by the Government of Canada’s Networks of Centres of Excellence program and academic partners, supports the development of technologies that accelerate the commercialization of stem cell- and biomaterials-based technologies and therapies. A network of academics, industry and entrepreneurs, CCRM aims to translate scientific discoveries into marketable products for patients with specialized team funding and infrastructure. CCRM launched in Toronto’s Discovery District on June 14, 2011. CCRM is hosted by the University of Toronto. CCRM sources and conducts diligence on intellectual property from around the globe, performing fee-for-service and development projects with academia and industry in the areas of cell reprogramming and engineering, cell manufacturing and biomaterials. CCRM has a fully resourced, 6,000 square foot development facility used to advance technologies for out-licensing or company creation. For more information: www.ccrm.ca
Institute for Research in Immunology and Cancer
An ultra-modern research hub and training centre located in the heart of the Université de Montréal, the Institute for Research in Immunology and Cancer (IRIC) was created in 2003 to shed light on the mechanisms of cancer and discover new, more effective therapies to counter this disease. IRIC operates according to a model that is unique in Canada. Its innovative approach to research has already led to discoveries that will, over the coming years, have a significant impact on the fight against cancer. For more information: www.iric.ca
Institute of Biomaterials and Biomedical Engineering
Founded in 1962, the Institute of Biomaterials and Biomedical Engineering (IBBME) is a unique tri-faculty graduate research unit at the University of Toronto. Supported by the Faculties of Applied Science and Engineering, Medicine, and Dentistry, IBBME comprises over 100 faculty members integrated into four research themes and encompassing over 250 graduate students. With vibrant multi- and trans-disciplinary research programs that range from stem cell bioengineering through nanotechnology, biomaterials, to assistive technologies, regenerative medicine, and clinical and rehabilitation engineering, IBBME researchers are finding innovative solutions to the world’s most pressing health care challenges. For more information: www.ibbme.utoronto.ca.